Relmada Therapeutics (RLMD) Total Non-Current Liabilities (2014 - 2026)

Relmada Therapeutics (RLMD) has 8 years of Total Non-Current Liabilities data on file, last reported at $12.9 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $12.9 million, up 190.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.9 million (up 190.59% YoY), and the FY2025 annual result was $6.4 million, down 37.52% from the prior year.
• Total Non-Current Liabilities climbed to $12.9 million in Q1 2026 per RLMD's latest filing, from $6.4 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $12.9 million in Q1 2026 and troughed at $4.4 million in Q1 2025.
• A 3-year average of $7.5 million and a median of $6.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities slumped 37.52% in 2025, then surged 190.59% in 2026.
• A 3-year view of Total Non-Current Liabilities shows it stood at $10.3 million in 2024, then tumbled by 37.52% to $6.4 million in 2025, then soared by 100.48% to $12.9 million in 2026.
• Business Quant data shows RLMD's Total Non-Current Liabilities at $12.9 million in Q1 2026, $6.4 million in Q4 2025, and $5.2 million in Q3 2025.